利伐沙班、达比加群与阿哌沙班在2431例髋膝关节置换患者口服血栓预防中的前瞻性队列比较研究:主要疗效结局与安全性特征
该前瞻性队列研究纳入2011至2015年间2431例接受全髋或全膝关节置换后使用利伐沙班、达比加群或阿哌沙班进行血栓预防的患者,比较症状性静脉血栓栓塞症(VTE)和大出血发生率。总体症状性VTE发生率为2%,利伐沙班在总体VTE预防(0.8% vs 2.6%)和深静脉血栓预防(0.3% vs 2.2%)方面优于达比加群(P < .01),也优于阿哌沙班(P < .01);三种药物大出血发生率无显著差异。
要点
- 总体症状性VTE发生率为2%,利伐沙班VTE预防效果优于达比加群和阿哌沙班(P < .01)。
- 利伐沙班深静脉血栓预防优于达比加群(0.3% vs 2.2%,P < .01)。
- 三种药物大出血发生率无显著差异,总体大出血率为1.2%。
核心结论
- 三种药物的症状性VTE发生率与已发表文献中低分子量肝素相当。
- 利伐沙班在VTE预防方面似乎优于阿哌沙班和达比加群。
- 三种药物的大出血发生率无统计学差异。
研究设计与样本
- 前瞻性队列比较研究,纳入2011至2015年间2431例接受全髋关节置换术(35天)或全膝关节置换术(14天)后使用一种直接口服抗凝药(DOAC)进行血栓预防的患者。
- 主要结局指标为症状性VTE发生率和大出血发生率;次要结局指标为伤口愈合问题和重返手术室需求。
- 二分类变量采用卡方检验或Fisher精确检验在三组间比较,并计算预设两两比较的相对危险度。
主要发现
- 总体症状性VTE发生率为2%。
- 利伐沙班总体VTE预防效果优于达比加群(0.8% vs 2.6%,P < .01)和阿哌沙班(0.8% vs 2.6%,P < .01)。
- 利伐沙班深静脉血栓预防优于达比加群(0.3% vs 2.2%,P < .01)。
- 总体大出血发生率为1.2%,三种药物间无显著差异。
关键数值与推荐
- 全髋关节置换术后DOAC血栓预防疗程为35天,全膝关节置换术后为14天。
- 症状性VTE总体发生率为2%,大出血总体发生率为1.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct oral anticoagulants (DOACs) have promised superior efficacy to low molecular weight heparins in the prevention of venous thromboembolism (VTE) in total hip and knee arthroplasty. However, there are concerns about raised associated bleeding and wound problems with these agents. This study aims to evaluate and compare the efficacy and safety of the 3 DOAC drugs: rivaroxaban, dabigatran and apixaban. METHODS: The primary outcome measures were rate of symptomatic VTE and major bleeding. Secondary outcome measures were wound healing problems and requirement for return to theater. A total of 2431 patients received one of the DOAC drugs as thromboprophylaxis following total hip arthroplasty (35 days) or total knee arthroplasty (14 days) between 2011 and 2015. Binary variables were compared between the 3 groups by using the chi-squared test or Fisher's exact test. Relative risks of selected primary and secondary end points were also calculated for the prespecified pairwise comparison. RESULTS: The overall symptomatic VTE rate was 2%. Rivaroxaban had a statistically significant superior efficacy for overall VTE prevention (0.8% vs 2.6%) compared with dabigatran (P < .01) and apixaban (P < .01), and deep vein thrombosis prevention (0.3% vs 2.2%) over dabigatran (P < .01). The overall rate of major bleeding was 1.2% with no significant difference observed between the 3 studied drugs. CONCLUSION: All 3 drugs had symptomatic VTE rates comparable with low molecular weight heparin from the published literature. Rivaroxaban appears to have superior efficacy in VTE prevention over apixaban and dabigatran. No statistical difference was observed for major bleeding with any of the 3 agents.
引用
- Highcock AJ, As-Sultany M, Finley R, et al. A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile. J Arthroplasty. 2020. PMID: 32674939. doi:10.1016/j.arth.2020.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。